NCT05951179Phase 2Recruiting

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Study sponsor: Protara Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2031-10Estimated
Enrollment · participants131Estimated
Source updated2026-08-24Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002 Measure: Cohort A: Incidence of high-grade Complete Response at any time by subgroup (BCG naive and BCG exposed > 24 months) according to central pathology after treatment with TARA-002. After: Measure: Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002.

Primary completion date changed

Before: May 2030. After: Oct 2031.

Check registry source

· 1 field changed

Planned enrollment increased by 4 participants

Before: 127 participants (planned). After: 131 participants (planned).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview